Shares of Tilray Inc (NASDAQ:TLRY – Get Rating) have earned an average rating of "Hold" from the twelve brokerages that are covering the stock, MarketBeat.com reports. Two investment analysts have rated the stock with a sell recommendation, five have assigned a hold recommendation and one has given a buy recommendation to the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $5.08.

A number of research analysts have issued reports on TLRY shares. Sanford C. Bernstein started coverage on Tilray in a research note on Tuesday, November 1st. They issued a "market perform" rating and a $3.90 price objective for the company. Haywood Securities reduced their price objective on Tilray to $3.50 in a research note on Thursday, October 13th. Alliance Global Partners dropped their price target on Tilray from $4.00 to $3.00 and set a "neutral" rating on the stock in a research report on Monday, January 9th. Finally, Cantor Fitzgerald upped their price target on Tilray from $4.15 to $4.50 and gave the company a "neutral" rating in a research report on Monday, October 10th.

Insiders Place Their Bets

In other news, Director Brendan Kennedy sold 350,000 shares of the firm's stock in a transaction that occurred on Monday, November 7th. The stock was sold at an average price of $3.78, for a total value of $1,323,000.00. Following the completion of the transaction, the director now owns 6,224,196 shares in the company, valued at approximately $23,527,460.88. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 2.54% of the company's stock.

Institutional Inflows and Outflows

Tilray Price Performance

Shares of TLRY opened at $3.20 on Monday. Tilray has a 52-week low of $2.52 and a 52-week high of $9.08. The company has a debt-to-equity ratio of 0.09, a quick ratio of 1.35 and a current ratio of 1.91. The business's 50 day moving average price is $3.22 and its two-hundred day moving average price is $3.44. The firm has a market cap of $1.97 billion, a PE ratio of -3.05 and a beta of 2.68.

Tilray (NASDAQ:TLRY – Get Rating) last released its quarterly earnings data on Monday, January 9th. The company reported ($0.06) EPS for the quarter, missing the consensus estimate of ($0.05) by ($0.01). The firm had revenue of $144.10 million for the quarter, compared to the consensus estimate of $157.21 million. Tilray had a negative net margin of 89.96% and a negative return on equity of 5.10%. The business's revenue for the quarter was down 7.1% compared to the same quarter last year. On average, equities analysts anticipate that Tilray will post -0.34 EPS for the current year.

About Tilray

(Get Rating)

Tilray, Inc engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc is headquartered in Nanaimo, Canada.

Featured Articles

• Get a free copy of the StockNews.com research report on Tilray (TLRY)
• Are Penny Stocks Worth it? Should You Invest in Penny Stocks?
• Zimmer Biomet Beats on Earnings, Growth May be Priced In
• AI Software Maker EPAM Boasts Biggest Tech-Sector Rally
• Ford Stock Going Forward After Big Earnings Flop
• Insiders And Institutions Buy Wolverine Worldwide

Receive News & Ratings for Tilray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tilray and related companies with MarketBeat.com's FREE daily email newsletter.